There are currently 159 candidates for the vaccines, 11 of which have already conducted the human trials and 8 have been approved to move forward with further human testing.

Moderna – RNA

CanSino Biologics – Adenovirus type 5

Inovio – DNA

BioNTech, Pfizer – RNA

University of Oxford/ Astrazeneca – Chimp Adenovirus

Novavax – Virus like particle

Merck & Co. – Nucleic acid

Johnson & Johnson – Ad 26

Sanofi, Glaxosmithkline – Protein based vaccine with GSK providing the adjuvant